Rheumatoid Arthritis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences

 Breaking News
  • No posts were found

Rheumatoid Arthritis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences

December 05
20:26 2023
Rheumatoid Arthritis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences

DelveInsight’s, “Rheumatoid Arthritis Pipeline Insight 2023” report provides comprehensive insights about 95+ companies and 100+ pipeline drugs in the Rheumatoid Arthritis pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Rheumatoid Arthritis Pipeline Report

  • DelveInsight’s Rheumatoid Arthritis pipeline report depicts a robust space with 95+ active players working to develop 100+ pipeline therapies for Rheumatoid Arthritis treatment.
  • The leading companies working in the Rheumatoid Arthritis Market include Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc. PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences Inc., ICMBIO, and others.
  • Promising Rheumatoid Arthritis Pipeline Therapies in the various stages of development etanercept, M2951, Adalimumab, methotrexate, ENBREL®, Enbrel, Certolizumab pegol, LY3871801, and others.
  • November 2023: SynAct Pharma Aps announced a study of Phase 2 clinical trials for 100 mg AP1189. The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate (MTX).
  • October 2023: Eli Lilly and Company announced a study of Phase 2 clinical trials for LY3871801. The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).
  • August 2023: Eli Lilly and Company announced a study of phase 4 clinical trials for Baricitinib and TNF Inhibitor. This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors concerning venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
  • August 2023: Teijin America Inc. announced a study of phase 1 clinical trials for TCK-276. The study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of multiple orally administered TCK-276 in both males and females with Rheumatoid Arthritis (RA).

 

Request a sample and discover the recent advances in Rheumatoid Arthritis Treatment Drugs @ Rheumatoid Arthritis Pipeline Outlook Report

 

In the Rheumatoid Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease known to adversely impact the joints of the body. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body; on the onset of disease, the immune response primarily attacks and harms the joints.

 

Find out more about Rheumatoid Arthritis Treatment Landscape @ Drugs for Rheumatoid Arthritis Treatment

 

Rheumatoid Arthritis Emerging Drugs Profile

  • SM03: SinoMab
  • SHR0302: Jiangsu Hengrui Medicine
  • RC18: RemeGen
  • Zalunfiban: CeleCor Therapeutics
  • ABBV-3373: Abbvie
  • Dazodalibep: Horizon Therapeutics
  • AP1189: Synact Pharma
  • Dekavil: Philogen

 

Rheumatoid Arthritis Pipeline Therapeutics Assessment

There are approx. 95+ key companies which are developing the Rheumatoid Arthritis therapies. The Rheumatoid Arthritis companies which have their Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. Phase I/II include, RHEACELL.

 

DelveInsight’s Rheumatoid Arthritis pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Rheumatoid Arthritis Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Rheumatoid Arthritis Pipeline Therapies @ Rheumatoid Arthritis Clinical Trials Assessment

 

Scope of the Rheumatoid Arthritis Pipeline Report

  • Coverage- Global
  • Rheumatoid Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Rheumatoid Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Rheumatoid Arthritis Companies- Yuyu Pharma Inc., Worg Pharmaceuticals, Vyne Therapeutics, Vaccinex Inc., Tiziana Life Sciences, Teijin Pharma, Taiho Pharmaceutical, Synermore Biologics Co., Ltd., Synact Pharma, Sorrento Therapeutics, Sonoma Biotherapeutics, SinoMab Bioscience Ltd, Silo Pharma, SFA Therapeutics, Servatus Biopharmaceuticals, SciRhom, R-Pharm, Rottapharm Biotech, ROS Therapeutics, RheumaGen, Revolo Biotherapeutics, RemeGen, Regen BioPharma Inc. PrecisionLife, Philogen, Pfizer, Oryn Therapeutics, Nurix, NovImmune, Novartis, Neutrolis Therapeutics, MyMD Pharmaceuticals, Modern Biosciences, Minghui Pharmaceutical Pty Ltd, MetrioPharm, Mesoblast, Lysatpharma GmbH, Lynk Pharmaceuticals, Landos Biopharma, Kymera Therapeutics, Kolon TissueGene, KLUS Pharma, Kiniksa Pharmaceuticals, Ltd., Kangstem Biotech, Jubilant Therapeutics, Jiangsu Hengrui Medicine, Janssen Research & Development, Intrinsic Medicine, Innocare Pharma Australia Pty Ltd, Immutep Limited, Imcyse, I-Mab Biopharma Co. Ltd., Iltoo Pharma, IGM Biosciences Inc., ICMBIO, and others.
  • Rheumatoid Arthritis Pipeline Therapies- etanercept, M2951, Adalimumab, methotrexate, ENBREL®, Enbrel, Certolizumab pegol, LY3871801, and others.

 

Dive deep into rich insights for new drugs for Rheumatoid Arthritis treatment, Visit @ Rheumatoid Arthritis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Rheumatoid Arthritis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Rheumatoid Arthritis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. SM03: SinoMab
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ABBV-3373: Abbvie
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SVT 6A4710: Servatus Biopharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. SYN060: Synermore Biologics Co., Ltd.
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. CABA-201: Cabaletta Bio
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Rheumatoid Arthritis Collaborations Assessment- Licensing / Partnering / Funding
  24. Rheumatoid Arthritis Unmet Needs
  25. Rheumatoid Arthritis Market Drivers and Barriers
  26. Appendix

 

For further information on the Rheumatoid Arthritis pipeline therapeutics, reach out to Rheumatoid Arthritis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-market

Related Articles

Categories